Finance

Beta
Lists
RV6:FRA
Charles River Lbrtrs ntrntl Inc
€153.90
+2.70%
(+4.05) 1D
Jun 4, 8:16:02 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for RV6...
Open
€153.90
High
€153.90
Low
€153.90
Mkt. cap
8.97B
Avg. vol.
19.00
Volume
0.00
52-wk high
€193.70
52-wk low
€117.65
No. of employees
19K
Open
€153.90
High
€153.90
Low
€153.90
Mkt. cap
8.97B
Avg. vol.
19.00
Volume
0.00
52-wk high
€193.70
52-wk low
€117.65
No. of employees
19K
News stories
From sources across the web
Profile
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Lbrtrs ntrntl Inc
CEOJames C. Foster
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth care
Websitecriver.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.03B
1.00B
994.23M
995.83M
Cost of goods sold
648.60M
652.72M
665.36M
672.79M
Cost of revenue
648.60M
652.72M
665.36M
672.79M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
185.82M
173.64M
192.02M
149.12M
Operating expense
211.51M
201.05M
284.04M
164.46M
Total operating expenses
860.10M
853.77M
949.40M
837.25M
Operating income
172.03M
151.08M
44.83M
158.58M
Other non operating income
154.00K
-22.62M
27.72M
-123.11M
EBT including unusual items
71.42M
87.20M
-294.10M
-29.94M
EBT excluding unusual items
143.32M
104.48M
35.18M
8.62M
Income tax expense
18.72M
31.64M
-17.81M
-15.14M
Effective tax rate
26.22%
36.29%
6.06%
50.56%
Other operating expenses
-
-
-
-
Net income
52.33M
54.42M
-276.56M
-14.84M
Net profit margin
5.07%
5.42%
-27.82%
-1.49%
Earnings per share
3.12
2.43
2.39
2.06
Interest and investment income
1.10M
1.42M
1.02M
1.03M
Interest expense
-29.97M
-25.40M
-23.78M
-26.74M
Net interest expenses
-28.87M
-23.98M
-22.76M
-25.71M
Depreciation and amortization charges
-
-
-
-
EBITDA
327.04M
165.25M
169.61M
225.73M
Gain or loss from assets sale
-
-
-
117.98M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer